期刊
CANCER RESEARCH
卷 74, 期 18, 页码 5008-5018出版社
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/0008-5472.CAN-13-2698
关键词
-
类别
资金
- Institut National de la Sante et de la Recherche Medicale
- Fondation ARC pour la recherche sur le cancer
- Fondation de France [00012068]
- Universite Pierre et Marie Curie, Universite Paris-Descartes, Institut National du Cancer [2011-1-PLBIO-06-INSERM 6-1, PLBIO09-088-IDF-KROEMER]
- CARPEM (Cancer Research for Personalized Medicine)
- Labex Immuno-Oncology [LAXE62_9UMS872 FRIDMAN]
Toll-like receptors (TLR) recognize pathogen molecules and danger-associated signals that stimulate inflammatory processes. TLRs have been studied mainly in antigen-presenting cells, where they exert important immune regulatory functions, but they are also expressed by epithelial tumor cells, where they have been implicated in tumor progression. In this study, we demonstrate that the injection of TLR7 agonist in NOD/SCID mice, in C57BL/6 wild-type, and TLR7-deficient mice grafted with lung adenocarcinoma tumor cells leads to increased tumor progression and chemotherapeutic resistance. In patients with non-small cell lung cancer, expression analyses revealed that high TLR7 expression was strongly associated with resistance to neoadjuvant chemotherapy and poor clinical outcomes. Our findings delineate a crucial role for TLR7 in lung cancer physiopathology. (C)2014 AACR.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据